Shigella treatment
Reading File
Searching PubMed
Shigella treatment antibiotics
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information from multiple authoritative textbooks. Here is the full synthesized answer:
Shigella (Shigellosis) Treatment
Overview
Shigellosis ranges from mild, self-limited watery diarrhea to severe dysentery with bloody stools, fever, and tenesmus. Treatment decisions depend on disease severity, patient immune status, local resistance patterns, and susceptibility testing.
Supportive Care (All Patients)
-
Oral rehydration is the cornerstone - severe dehydration is uncommon but fluid and electrolyte replacement is essential.
-
Antidiarrheal agents (e.g., loperamide, antimotility drugs) are contraindicated - they prolong illness, delay bacterial clearance, and increase complication rates.
-
Nutritional support: In resource-limited settings, vitamin A (200,000 IU) and zinc (20 mg/day; 10 mg/day for infants ≤6 months) for 10-14 days hasten clinical resolution.
-
Red Book 2021, p. 1041; Goldman-Cecil Medicine
When to Treat with Antibiotics
Not all cases require antibiotics:
- S. sonnei infections in healthy individuals are often self-limited within 48-72 hours and may not require therapy.
- WHO 2017 recommends no antibiotic treatment for non-bloody, non-febrile diarrheal episodes (including Shigella).
- CDC recommends limiting antibiotic treatment to patients who are immunocompromised, have severe illness (requiring hospitalization), or have invasive disease/complications.
- For public health reasons (reducing fecal shedding and transmission), treatment is still broadly recommended.
Antibiotics are recommended for:
-
Severe disease (high fever, bloody diarrhea, dysentery)
-
Immunosuppressed patients (treat 7-10 days)
-
Neonates, malnourished children
-
Outbreak control settings
-
Red Book 2021, p. 1040-1041
Antibiotic Regimens
Adults
| Setting | Drug | Dose/Duration |
|---|---|---|
| First-line (susceptible) | Ciprofloxacin | 500 mg once daily x 3 days (oral) |
| Severe/parenteral | Ceftriaxone | 1 g IV/IM every 24h x 3 days |
| Ciprofloxacin-resistant | Azithromycin | 1 g x 1 day OR 500 mg day 1, then 250 mg days 2-5 |
| Ciprofloxacin-resistant (alt.) | Cefixime | 400 mg once daily x 3 days |
| If susceptible (alt.) | TMP-SMX | 160/800 mg twice daily x 5 days |
Children
| Setting | Drug | Dose/Duration |
|---|---|---|
| First-line (susceptible) | Ciprofloxacin | 15 mg/kg twice daily x 3 days (oral) |
| Severe/parenteral | Ceftriaxone | 50-100 mg/kg once daily x 3 days IV/IM |
| Ciprofloxacin-resistant | Azithromycin | 12 mg/kg on day 1, then 6 mg/kg daily on days 2-4 (4-day course) |
| Ciprofloxacin-resistant (alt.) | Cefixime | 8 mg/kg once daily x 3 days |
| If susceptible (alt.) | TMP-SMX | 4 mg/kg/day TMP + 20 mg/kg/day SMZ twice daily x 5 days |
| Developing countries (adjunct) | Zinc | 20 mg/day (10 mg for ≤6 months) x 10-14 days |
- Goldman-Cecil Medicine, Figure 285-1; Jawetz Medical Microbiology 28e
Antimicrobial Resistance - A Growing Crisis
This is now the central challenge in Shigella management:
- Ampicillin: ~59% of US isolates resistant (1999-2015)
- TMP-SMX: ~43% resistant - no longer suitable as empiric therapy
- Ciprofloxacin: Resistance jumped from <1% pre-2015 to ~10% by 2017; ciprofloxacin-resistant S. sonnei emerged in South Asia and spread globally
- Azithromycin: ~24% decreased susceptibility by 2017; resistance is particularly common in MSM and people with HIV
- Ceftriaxone (3rd-gen cephalosporins): Rare in the US but reported in Asia; ESBL- and carbapenemase-producing strains emerging
Key rule: If Shigella MIC for ciprofloxacin is ≥0.12 mcg/mL, do NOT use fluoroquinolones - even if the lab reports "susceptible." This threshold is associated with treatment failure and prolonged shedding.
- Red Book 2021, p. 1033-1034; Goldman-Cecil Medicine, p. 3157
Special Situations
| Situation | Approach |
|---|---|
| MSM / HIV patients | High suspicion for azithromycin resistance; obtain susceptibility testing; consider ID consult |
| Immunocompromised | Treat for 7-10 days (vs. 3-5 days for normal hosts) |
| S. dysenteriae type 1 | Higher risk of HUS, toxic megacolon, bacteremia; aggressive treatment warranted |
| Bacteremia | Culture blood; IV ceftriaxone preferred |
| HUS | Supportive care; role of antibiotics unclear (may worsen in STEC-HUS but Shigella-associated HUS is different) |
| Surgical complications (perforation, obstruction, peritonitis) | Surgical intervention may be required |
Agents to Avoid
- Amoxicillin: Ineffective due to rapid GI absorption (unlike ampicillin)
- Rifaximin: Not effective against invasive Shigella infections
- Antimotility agents (loperamide, opioids): Contraindicated
Diagnosis Note
Culture remains the gold standard and guides therapy. If multiplex PCR is used, reflex culture should still be obtained to allow susceptibility testing. Blood cultures are warranted in severely ill, immunocompromised, or malnourished patients.
Regarding Recent Evidence
The 2024-2025 systematic reviews (PMID 39472797 and 39827134) confirm a high prevalence of ESBL- and carbapenemase-producing Shigella strains in Africa, reinforcing that empiric antibiotic selection must be guided by local resistance data. The global rise in multidrug-resistant strains - including XDR Shigella (resistant to all recommended first- and second-line agents) - is an urgent concern, particularly for travelers returning from South/Southeast Asia.
This is a shared conversation. Sign in to Orris to start your own chat.